Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Raphael Pharmaceutical Inc. (Raphael Pharmaceutical or the Company) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative research…